Compare VIPS & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIPS | CRSP |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.2B |
| IPO Year | 2012 | 2016 |
| Metric | VIPS | CRSP |
|---|---|---|
| Price | $12.74 | $49.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 23 |
| Target Price | $16.02 | ★ $85.63 |
| AVG Volume (30 Days) | ★ 2.2M | 1.4M |
| Earning Date | 11-19-2026 | 11-09-2026 |
| Dividend Yield | ★ 4.86% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $289,590,000.00 |
| Revenue This Year | N/A | $1,052.09 |
| Revenue Next Year | $0.87 | $273.88 |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | N/A | ★ 9169.85 |
| 52 Week Low | $12.02 | $44.12 |
| 52 Week High | $20.49 | $67.66 |
| Indicator | VIPS | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 48.12 | 41.28 |
| Support Level | $12.12 | $45.61 |
| Resistance Level | $12.81 | $60.71 |
| Average True Range (ATR) | 0.32 | 2.64 |
| MACD | 0.03 | -0.27 |
| Stochastic Oscillator | 38.25 | 17.19 |
Vipshop is a leading Chinese online discount retailer offering branded products at attractive discounts of 10%-90% off their original price through daily flash sales. It operates warehousing, retailing, product procurement, software development, and information technology support in-house while outsourcing to third-party logistics providers for distribution and shipments. Branded products on Vipshop's platform are sourced mostly through a consignment model with global brand partners. As of March 31, 2025, Eric Ya Shen, chair and CEO, had 64.5% voting rights. Leading Chinese social media firm and strategic shareholder Tencent also holds a 12.5% interest.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.